Andecaliximab Biosimilar Monoclonal Antibody (MMP-9) for Research
Pre-Made Andecaliximab biosimilar, Whole mAb, Anti-MMP9/MMP-9 Antibody: Anti-CLG4B/GELB/MANDP2 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Andecaliximab (INN; development code GS-5745) is an experimental humanized monoclonal antibody designed for the treatment of cancer and inflammatory diseases.
Order Information
| Catalog No. | Package | List Price(In USD) | Discount off | Discount Price |
|---|---|---|---|---|
| GMP-Bios-ab-024-1mg | 1mg | 618 |
Size: 1mg | 10mg | 100mg
Product Details
| Products Name (INN Index) | Pre-Made Andecaliximab biosimilar, Whole mAb, Anti-MMP9/MMP-9 Antibody: Anti-CLG4B/GELB/MANDP2 therapeutic antibody |
| INN Name | Andecaliximab |
| Target | MMP-9 |
| Format | Whole mAb |
| Derivation | Chimeric (Mouse/Human) |
| Species Reactivity | Human |
| CH1 Isotype | IgG4 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-III |
| Est. Status | Discontinued |
| 100% SI Structure | 5th9:HL:IM:JN |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2016 |
| Year Recommended | 2017 |
| Companies | Gilead Sciences |
| Conditions Approved | na |
| Conditions Active | na |
| Conditions Discontinued | Chronic obstructive pulmonary disease;Crohn's disease;Cystic fibrosis;Rheumatoid arthritis;Ulcerative colitis;Gastric cancer;Solid tumours;Glioblastoma |
| Development Tech | na |
About target - MMP9
1. Protein Matrix metalloproteinase-9
2. Gene MMP9
3. Organism Homo sapiens (Human)
Function
Matrix metalloproteinase that plays an essential role in local proteolysis of the extracellular matrix and in leukocyte migration (PubMed:2551898, PubMed:1480034, PubMed:12879005).
Could play a role in bone osteoclastic resorption (By similarity).
Cleaves KiSS1 at a Gly-|-Leu bond (PubMed:12879005).
Cleaves NINJ1 to generate the Secreted ninjurin-1 form (PubMed:32883094).
Cleaves type IV and type V collagen into large C-terminal three quarter fragments and shorter N-terminal one quarter fragments (PubMed:1480034).
Degrades fibronectin but not laminin or Pz-peptide.
Miscellaneous
In the arthritis patient this enzyme might contribute to the pathogenesis of joint destruction and might constitute a useful marker of disease status.
Catalytic activityi
Cleavage of gelatin types I and V and collagen types IV and V. EC:3.4.24.35
Cofactor
Protein has several cofactor binding sites:
Zn2+
Note: Binds 2 Zn2+ ions per subunit.
Ca2+
Note: Binds 3 Ca2+ ions per subunit.
Activity regulationi
Inhibited by histatin-3 1/24 (histatin-5). Inhibited by ECM1.

